KESHAV
USD 886.67
Sold 1,800+Offline Hong Kong pharmacy with 100% genuine product guarantee
Elafibranor received accelerated approval in the United States in June 2024.
10000 in stock
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
Elafibranor How It Works How It Works ，
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO ， [ Precautions (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
5 Precautions IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
11 GFT1007 PPAR pH 1.2 6.8 ， pH 7.5 ， DMSO ， C₂₂H₂₄O₄S， 384.49 g/mol， 2-(2,6- -4-{3-[4-( ) ]-3- -1- -1- } )-2- ， IQIRVO 80 mg ，
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO ， [ Precautions (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
5 Precautions IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
8.1 ， IQIRVO ， elafibranor ， / ， IQIRVO ，
12 12.1 How It Works GFT1007 PPAR ， PPAR-α PPAR-γ PPAR-δ ， PBC PPAR-α PPAR-δ ，PPAR-δ 21 FGF21 CYP7A1 ，CYP7A1 PPAR ，elafibranor GFT1007 PPAR-α EC50 46 nM 14 nM，Em 0.05 0.05
13 13.1 2 CD-1 ， elafibranor 1 3 10 30 mg/kg/ ， elafibranor GFT1007 AUC， 0.007 0.14 0.003 0.16 Sprague-Dawley ， elafibranor 10 mg/kg/ elafibranor GFT1007 AUC 0.36 ， 30 mg/kg/ elafibranor GFT1007 AUC 2.1 ，elafibranor
14 1 (NCT04526665) IQIRVO 161 (UDCA) (PBC) IQIRVO 80 mg (n=108) (n=53)， ， 52 ， UDCA (ALP) ≥ (ULN) 1.67 ， (TB) ≤ 2
Indications
Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.
How It Works
Elafibranor How It Works How It Works ，
Dosage
2 ， ， / (2.1) 80 mg， (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO ， [ Precautions (5.3)， (8.1, 8.3)] 2.2 IQIRVO 80 mg， [ (12.3)] 2.3 IQIRVO 4 4 ， [ (7.2)]
Precautions
5 Precautions IQIRVO ， (CPK) ， IQIRVO 5.1 IQIRVO ， 5.2
